BioCentury | Oct 17, 2020
Finance

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

...is in a Phase IIa trial to treat major depressive disorder and perimenopausal disorder. Its calcium channel T-type...
BioCentury | Oct 1, 2020
Distillery Therapeutics

Calcium channel-targeting peptide to prevent hypertrophic cardiomyopathy

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy A peptide targeting the cardiac calcium channel L-type α-interaction domain, a cytoplasmic portion the channel’s α1C subunit, could prevent hypertrophic cardiomyopathy. In a mouse model of the disease caused by a...
BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

...in clinical, regulatory and sales milestones in a deal that gives Jazz CX-8998. While the calcium channel T-type...
BioCentury | Dec 12, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest treatment with cilnidipine or inhibiting DNM1L could help treat MI. Screening of antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that...
BioCentury | Oct 11, 2018
Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

...use a different primary endpoint than that of the Phase II trial. CX-8998 is a calcium channel T-type...
...CX-8998 to treat generalized epilepsy with absence seizures. Idorsia Ltd. (SIX:IDIA) is also developing a calcium channel T-type...
...to treat epilepsy. Cavion Inc., Charlottesville, Va. Product: CX-8998 Business: Neurology Molecular target: Calcium channel T-type Description: Calcium channel T-type...
BioCentury | Oct 8, 2018
Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

...use a different primary endpoint than that of the Phase II trial. CX-8998 is a calcium channel T-type...
...developing a calcium channel T-type blocker, ACT-709478, which is in Phase I testing to treat epilepsy. Chris Lieu CX-8998 Cavion Inc. Calcium channel T-type Essential...
BioCentury | Feb 14, 2018
Preclinical News

Three targets in the same brain region could alleviate depression

...the animals’ depression-like symptoms. The researchers found the effects depended on the NMDA receptor and calcium channel T-type...
...depression-like behaviors. According to BioCentury's BCIQ database, no companies are developing compounds against KCNJ10 or calcium channel T-type...
...depression without inhibiting NMDA receptors (see BioCentury Innovations May 26, 2016) . Sandi Wong ketamine Johnson & Johnson Zhejiang University Calcium channel T-type NMDA...
BioCentury | May 8, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting the calcium channel L-type could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a calcium channel L-type inhibitor decreased MS symptom scores,...
BioCentury | Mar 30, 2017
Distillery Therapeutics

Cancer

...INDICATION: Brain cancer Cell culture and mouse studies identified calcium channel T-type and potassium channel inhibitors that could...
...of a library of ion channel blockers against primary human glioblastoma cell lines identified a calcium channel T-type...
...for brain cancer and solid tumors and preclinical testing for ovarian and pancreatic cancers. TARGET/MARKER/PATHWAY: Calcium channel T-type...
BioCentury | Jul 20, 2015
Clinical News

Horizant gabapentin enacarbil: Phase II started

XenoPort said NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA) began the double-blind, placebo-controlled, U.S. Phase II NCIG-006 trial to evaluate 600 mg oral Horizant twice daily for 26 weeks in about 350 patients....
Items per page:
1 - 10 of 37